By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the market closed Monday second-quarter revenue growth of 162 percent, and said that it is seeking a new CEO for the firm, which completed its first quarter since going public in the US.

The California-based molecular diagnostics firm, which formerly was based in the UK and known as Osmetech, brought in total revenues of $650,712 for the three months ended June 30, compared to $248,568 for the second quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.